MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection

Biomaterials

Volumn 33, Issue 19, 2012, Pages 4836-4842

  Kim, Jang Il ^a,b   Kim, Bora ^c   Chun, ChangJu ^d   Lee, Seung Hoon ^c   Song, Soo Chang ^a,b  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c National Cancer Center   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Brain tumors; Imaging agents; Irinotecan; MRI monitored long term therapeutic hydrogel; Phosphazenes

Indexed keywords

ANTICANCER DRUG; BODY TEMPERATURE; BRAIN TUMORS; HYDROGEL SYSTEM; IMAGING AGENT; INJECTABILITY; INTRATUMORAL INJECTION; INTRAVENOUS INJECTIONS; IRINOTECAN; LOCAL DELIVERY; LOCALIZABILITY; MR IMAGING; PHOSPHAZENES; PHYSICAL MIXING; PIN HOLES; SIDE EFFECT; SURGICAL OPERATION; SURGICAL RESECTION; SURGICAL TREATMENT; SUSTAINED DRUG RELEASE; THERAPEUTIC AGENTS; THERMO SENSITIVE; TUMOR GROWTH;

BIOCOMPATIBILITY; BIODEGRADATION; BRAIN; CHEMOTHERAPY; COAGULATION; DRUG PRODUCTS; GELATION; HYDROGELS; MAGNETIC RESONANCE IMAGING; SURGERY; TUMORS;

NEUROIMAGING;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BODY TEMPERATURE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEMALE; GELATION; HEAT SENSITIVITY; HYDROGEL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LONG TERM THERAPEUTIC HYDROGEL SYSTEM; MAGNETISM; NEUROIMAGING; NEUROMONITORING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEREOTACTIC TREATMENT; SUSTAINED DRUG RELEASE; VISCOSITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROGEL; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; POLYMERS;

EID: 84859819685     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.048     Document Type: Article

References (26)

1. Newton H.B. Handbook of brain tumor chemotherapy 2006, 3-20. Elsevier/Academic Press, Boston. A. Ray-Chaudhury (Ed.).
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Castro M.G., Cowen R., Williamson I.K., David A., Jimenez-Dalmaroni M.J., Yuan X., et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003, 98:71-108.
4. Bouffet E., Tabori U., Huang A., Bartels U. Possibilities of new therapeutic strategies in brain tumors. Cancer Treat Rev 2010, 36:335-341.
5. Lee Koo Y.-E., Reddy G.R., Bhojani M., Schneider R., Philbert M.A., Rehemtulla A., et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006, 58:1556-1577.
6. Frappaz D., Chinot O., Bataillard A., Hassel M.B., Capelle L., Chanalet S., et al. Summary version of the standards, options and recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 2003, 89:S73-S83.
7. Brown P.D., Buckner J.C., O'Fallon J.R., Iturria N.L., Brown C.A., O'Neill B.P., et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 2003, 21:2519-2524.
8. Taphoon M.J.B. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol 2003, 30:45-48.
9. Newton H.B. Handbook of brain tumor chemotherapy 2006, 262-273. Elsevier/Academic Press, Boston. M.D. Doolittle, T.P. Murillo, E.A. Neuwelt (Eds.).
10. Perry J., Chambers A., Spithoff K., Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 2007, 14:189-194.
11. Weber E.L., Goebel E.A. Cerebral edema associated with gliadel wafers: two case studies. Neuro Oncol 2005, 7:84-89.
12. Lin S.H., Kleinberg L.R. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 2008, 8:343-359.
13. Attenello F.J., Mukherjee D., Datoo G., McGirt M.J., Bohan E., Weingart J.D., et al. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008, 15:2887-2893.
14. Hart M.G., Grant R., Garside R., Rogers G., Somerville M., Stein K. Chemotherapeutic wafers for high grade glioma (review). Cochrane Database Syst Rev 2008, CD007294.
15. Gallego J.M., Barcia J.A., Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir 2007, 149:261-265.
16. Olson J.J., McKenzie E., Skurski-Martin M., Zhang Z., Brat D., Phuphanich S. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neuro Oncol 2008, 90:293-299.
17. Darakchiev B.J., Albright R.E., Breneman J.C., Warnick R.E. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 2008, 108:236-242.
18. Kim J.I., Chun C.J., Kim B., Hong J.M., Cho J.-K., Lee S.H., et al. Thermosensitive/magnetic poly(organophosphazene) hydrogel as a long-term magnetic resonance contrast platform. Biomaterials 2012, 33:218-224.
19. Kim J.I., Lee B.S., Chun C.J., Cho J.-K., Kim S.-Y., Song S.-C. Long-term theranostic hydrogel system for solid tumors. Biomaterials 2012, 33:2251-2259.
20. Lee B.H., Song S.-C. Synthesis and characterization of biodegradable thermosensitive poly(organophosphazene) gels. Macromolecules 2004, 37:4533-4537.
21. 4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004, 126:273-279.
22. Turner C.D., Gururangan S., Eastwood J., Bottom K., Watral M., Beason R., et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 2002, 4:102-108.
23. Bomgaars L.R., Bernstein M., Krailo M., Kadota R., Das S., Chen Z., et al. Phase II trial of irinotecan in children with refractory solid tumors: a children's oncology group study. J Clin Oncol 2007, 25:4622-4627.
24. Horiike A., Kudo K., Miyauchi E., Ohyanagi F., Kasahara K., Horai T., et al. Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. Br J Cancer 2011, 105:1131-1136.
25. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
26. Swindle K.E., Hamilton P.D., Ravi N. In situ formation of hydrogels as vitreous substitutes: viscoelastic comparison to porcine vitreous. J Biomed Mater Res Part A 2008, 87:656-665.